|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
54,830,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Vera Therapeutics is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Co.'s primary product candidate, atacicept, a self-administered fusion protein that blocks both blisibimod and APRIL, is being evaluated for the treatment of immunoglobulin A nephropathy in a global, randomized, double-blind, placebo-controlled clinical trial. Co. has obtained worldwide, exclusive development and commercial rights from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., for MAU868, a potentially monoclonal antibody to treat BK viremia infections.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
161,290 |
4,952,633 |
Total Buy Value |
$0 |
$0 |
$4,999,990 |
$42,324,664 |
Total People Bought |
0 |
0 |
1 |
8 |
Total Buy Transactions |
0 |
0 |
1 |
26 |
Total Shares Sold |
92,517 |
247,545 |
2,132,004 |
2,207,972 |
Total Sell Value |
$3,561,659 |
$9,784,376 |
$62,783,959 |
$64,248,783 |
Total People Sold |
2 |
4 |
6 |
8 |
Total Sell Transactions |
7 |
12 |
16 |
29 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Commodore Capital Lp |
10% Owner |
|
2023-06-20 |
4 |
B |
$15.17 |
$6,799,004 |
I/I |
448,217 |
5,450,000 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2023-06-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,001,783 |
|
- |
|
Seidenberg Beth C |
Director |
|
2023-03-28 |
4 |
B |
$7.24 |
$173,192 |
I/I |
23,908 |
1,946,995 |
2.1 |
- |
|
Seidenberg Beth C |
Director |
|
2023-03-27 |
4 |
B |
$7.24 |
$11,830 |
I/I |
1,633 |
1,923,087 |
2.1 |
- |
|
Seidenberg Beth C |
Director |
|
2023-03-24 |
4 |
B |
$7.24 |
$13,272 |
I/I |
1,833 |
1,921,454 |
2.1 |
- |
|
Seidenberg Beth C |
Director |
|
2023-03-20 |
4 |
B |
$7.21 |
$110,033 |
I/I |
15,252 |
1,919,621 |
2.1 |
- |
|
Seidenberg Beth C |
Director |
|
2023-03-17 |
4 |
B |
$7.12 |
$526,882 |
I/I |
74,045 |
1,904,369 |
2.1 |
- |
|
Seidenberg Beth C |
Director |
|
2023-03-16 |
4 |
B |
$7.09 |
$426,268 |
I/I |
60,097 |
1,830,324 |
2.1 |
- |
|
Seidenberg Beth C |
Director |
|
2023-03-15 |
4 |
B |
$7.12 |
$234,010 |
I/I |
32,844 |
1,770,227 |
2.1 |
- |
|
Grant Sean |
CHIEF FINANCIAL OFFICER |
|
2023-03-14 |
4 |
GA |
$0.00 |
$0 |
I/I |
14,285 |
15,277 |
|
- |
|
Grant Sean |
CHIEF FINANCIAL OFFICER |
|
2023-03-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
14,285 |
35,648 |
|
- |
|
Seidenberg Beth C |
Director |
|
2023-03-10 |
4 |
B |
$7.16 |
$343,485 |
I/I |
48,003 |
1,737,383 |
2.1 |
- |
|
Seidenberg Beth C |
Director |
|
2023-03-03 |
4 |
B |
$7.25 |
$7,245 |
I/I |
1,000 |
1,689,380 |
2.1 |
- |
|
Seidenberg Beth C |
Director |
|
2023-03-02 |
4 |
B |
$7.24 |
$169,322 |
I/I |
23,378 |
1,688,380 |
2.1 |
- |
|
Seidenberg Beth C |
Director |
|
2023-03-01 |
4 |
B |
$7.25 |
$725 |
I/I |
100 |
1,665,002 |
2.02 |
- |
|
Seidenberg Beth C |
Director |
|
2023-02-23 |
4 |
B |
$7.24 |
$1,447 |
I/I |
200 |
1,664,902 |
2.02 |
- |
|
Seidenberg Beth C |
Director |
|
2023-02-13 |
4 |
B |
$7.20 |
$72,490 |
I/I |
10,072 |
1,664,702 |
2.1 |
- |
|
Seidenberg Beth C |
Director |
|
2023-02-09 |
4 |
B |
$7.25 |
$2,900 |
I/I |
400 |
1,654,630 |
2.1 |
- |
|
Seidenberg Beth C |
Director |
|
2023-02-08 |
4 |
B |
$7.22 |
$327,478 |
I/I |
45,357 |
1,654,230 |
2.1 |
- |
|
Seidenberg Beth C |
Director |
|
2023-02-07 |
4 |
B |
$7.08 |
$622,728 |
I/I |
87,956 |
1,608,873 |
2.1 |
- |
|
Grant Sean |
Chief Financial Officer |
|
2023-02-06 |
4/A |
B |
$7.00 |
$99,995 |
D/D |
14,285 |
49,933 |
2.74 |
- |
|
Young Joseph R |
SVP, Finance, Chief Acct Offcr |
|
2023-02-06 |
4/A |
B |
$7.00 |
$39,998 |
D/D |
5,714 |
22,679 |
2.74 |
- |
|
Seidenberg Beth C |
Director |
|
2023-02-06 |
4 |
B |
$7.03 |
$925,162 |
I/I |
131,602 |
1,520,917 |
2.1 |
- |
|
Longitude Prime Fund, L.p. |
10% Owner |
|
2023-02-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,714,285 |
|
- |
|
Tammenoms Bakker Juliet |
10% Owner |
|
2023-02-06 |
4 |
B |
$7.00 |
$11,999,995 |
I/I |
1,714,285 |
1,714,285 |
1.5 |
- |
|
138 Records found
|
|
Page 2 of 6 |
|
|